We Target Chronic Inflammation
Recognizing the link between inflammation and numerous chronic diseases, Halia is pioneering targeting a specific inflammatory pathway, NLRP3, with an allosteric inhibitor to disrupt chronic inflammation. The goal of this method is to reduce inflammation and help reset this inflammatory pathway, potentially treating neurodegeneration and inflammatory diseases to improve quality of life and promote longevity.
Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.
Cancer

Live Better, Longer
We recognize that patients want to improve their health. Halia is dedicated to disrupting chronic inflammation to treat or prevent neurodegeneration and inflammatory diseases to improve quality of life and promote longevity.
NLRP3 Inflammasome:
Our drug targets to disrupt
chronic inflammation
Inflammation is an essential biological response of the human immune system that protects against disease. However, when dysregulated, inflammation can become a driver of disease by promoting a persistent, systemic immune response that fuels the development of many chronic diseases.1
One of the primary mechanisms mediating the persistent, systemic inflammatory response is activating a large protein complex called the NLRP3 inflammasome. The inflammasome activation produces pro-inflammatory signaling proteins, which contribute considerably to disease-causing inflammation.2

Science for longevity and quality of life
Our founders are renowned scientists with experience in drug discovery for oncology and neurodegeneration. We have made fundamental discoveries, identifying drug candidates that may potentially treat multiple disorders, including Alzheimer’s disease and other neurodegenerative disorders, as well as cancers and obesity.

Be a part of health history:

Schedule a meeting

Contact us

Participate in a trial
In the News
Targeted Oncology – HT-6184 Advances to Second Stage of Phase 2 Trial in LR-MDS
Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk MDS. Jordyn Sava December 17, 2024 The second stage of a phase 2 trial exploring the first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor HT-6184 for the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) is launching...
Longevity Technology – Promising data from Phase 2 study in myelodysplastic syndrome has potential implications for wider application in age-related diseases
Read this article on the website US biotech Halia Therapeutics has announced promising topline findings from its ongoing Phase 2 clinical trial of its oral treatment for lower-risk myelodysplastic syndromes. The drug, HT-6184, targets the NEK7 protein, which is critical to the activation of the NLRP3 inflammasome, a protein complex that drives inflammatory responses implicated in many...
EndPoints News – Halia Therapeutics takes NLRP3 inhibitor into final stage of Phase 2 trial
Read this article on the website Halia Therapeutics is moving its lead asset into the second part of a mid-stage trial following initialpositive data in patients with an early form of blood cancer that affects the bone marrow. The Utah-based biotech is investigating its oral NEK7/NLRP3 inflammasome inhibitor, dubbedHT-6184, in patients with lower-risk myelodysplastic syndromes. Patients with MDS...